ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of ...
MDX2003 targets CD19 and CD20 on B cells and CD3 and CD28 on T cells, enhancing antitumor activity and reducing antigen loss. The therapy's design limits cytokine release syndrome, showing improved ...
Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer The authors report on a prognostic tool (CD3 ...
A panelist highlights promising early-phase trial data on trispecific antibodies targeting multiple myeloma antigens and CD3, emphasizing their high response rates, manageable safety profiles, and ...
Excalipoint Therapeutics closed an oversubscribed $68.7 million seed financing, one of the largest early-stage rounds for a Chinese biotechnology company, to advance its pipeline of six T-cell engager ...
SHANGHAI--(BUSINESS WIRE)--ITabMed Ltd., a clinical-stage biotech company in China, announced the IND approval from China National Medical Products Administration (NMPA) for A-337, a CD3-activating bi ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners (MOLN) AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results